Progenics
From Verify.Wiki
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics has two commercial products, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, which is partnered with Bausch Health Companies, Inc.; and AZEDRA, for the treatment of unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy.
| |
Type | Public |
Founded | 1988 |
Headquarters | New York, New York |
Number of employees | 51-200 employees |
Contents
History
Controversies
Top 5 Recent Tweets
Date | Author | Comment |
---|---|---|
March 31, 2023 | urotoday | #TumorBoard reviewing the use of PSMA PET in #ProstateCancer - Gleason 3+3=6 GG 1, PALB2 mutations. @HJacene… https://t.co/BJFJ75rbGp |
March 30, 2023 | urotoday | #TumorBoard Reviewing the Use of PSMA PET in #ProstateCancer Gleason 4+4=8 GG 4, PI-RADS 5 Lesion, Possible Seminal… https://t.co/Mkr6UuP7Nq |